Fast Facts
Company Overview:
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists.
Founded:
1996
Employees:
Approximately 245 employees (as of September 30, 2012)
Headquarters:
3611 Valley Centre Drive, Suite 400, San Diego, California 92130
Exchange & Symbol:
NASDAQ Global Select Market; SNTS
Commercial Products:
- Endocrinology
- GLUMETZA® (metformin hydrochloride extended release tablets) As with all metformin products, GLUMETZA has a boxed warning for lactic acidosis. Please click here for Important Safety Information and Full Prescribing Information, including boxed warning.
- CYCLOSET® (bromocriptine mesylate)
- FENOGLIDE® (fenofibrate)
Investigational Products*:
- RUCONEST®(recombinant human C1 esterase inhibitor)
- Rifamycin SV MMX®
- SAN-300
*Not approved by the FDA.
Senior Management:
- Gerald T. Proehl - Director, President and Chief Executive Officer
- Wendell Wierenga, Ph.D. - Executive Vice President, Research and Development
- E. David Ballard II, M.D. - Senior Vice President, Medical Affairs and Pharmacovigilance
- Maria Bedoya-Toro, Ph.D. - Senior Vice President, Regulatory Affairs and Quality Assurance
- Debra P. Crawford - Senior Vice President, Chief Financial Officer, Treasurer and Secretary
- Julie A. DeMeules - Senior Vice President, Human Resources
- William C. Denby, III - Senior Vice President, Commercial Operations
- Carey J. Fox - Senior Vice President, General Counsel
- Warren E. Hall - Senior Vice President, Manufacturing and Product Development
- Michael D. Step - Senior Vice President, Corporate Development
- Mark C. Totoritis, M.D. - Senior Vice President, Clinical Research
- Blake A. Boland - Vice President, Sales
- Teri L. Chuppe - Vice President, Corporate Controller
- Jonathan M. Hee - Vice President, Commercial Affairs
- Martha L. Hough - Vice President, Finance and Investor Relations
- Thomas J. Joyce - Vice President, Marketing and National Accounts
Investor & Media Inquiries858-314-5824 IR@santarus.com |
Business Development Inquiries858-314-5777 BD@santarus.com |
Sign Up for E-Mail AlertsAutomatically receive financial and general information.Subscribe Now |